These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19341107)

  • 1. Analgesic effect of a polypeptide inhibitor of the TRPV1 receptor in noxious heat pain models.
    Andreev YA; Kozlov SA; Kozlovskaya EP; Grishin EV
    Dokl Biochem Biophys; 2009; 424():46-8. PubMed ID: 19341107
    [No Abstract]   [Full Text] [Related]  

  • 2. Peptide Blocker of Ion Channel TRPV1 Exhibits a Long Analgesic Effect in the Heat Stimulation Model.
    Sintsova OV; Palikov VA; Palikova YA; Klimovich AA; Gladkikh IN; Andreev YA; Monastyrnaya MM; Kozlovskaya EP; Dyachenko IA; Kozlov SA; Leychenko EV
    Dokl Biochem Biophys; 2020 Jul; 493(1):215-217. PubMed ID: 32894469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of TRPV channel block on polymodal activation of rat cutaneous nociceptors in vitro.
    St Pierre M; Reeh PW; Zimmermann K
    Exp Brain Res; 2009 Jun; 196(1):31-44. PubMed ID: 19404626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analgesic compound from sea anemone Heteractis crispa is the first polypeptide inhibitor of vanilloid receptor 1 (TRPV1).
    Andreev YA; Kozlov SA; Koshelev SG; Ivanova EA; Monastyrnaya MM; Kozlovskaya EP; Grishin EV
    J Biol Chem; 2008 Aug; 283(35):23914-21. PubMed ID: 18579526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
    Gunthorpe MJ; Chizh BA
    Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venom Peptide Toxins Targeting the Outer Pore Region of Transient Receptor Potential Vanilloid 1 in Pain: Implications for Analgesic Drug Development.
    Hwang SM; Jo YY; Cohen CF; Kim YH; Berta T; Park CK
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting TRPV1 for pain relief: limits, losers and laurels.
    Szallasi A; Sheta M
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1351-69. PubMed ID: 22780443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New polypeptide components from the Heteractis crispa sea anemone with analgesic activity].
    Kozlov SA; Andreev IaA; Murashev AN; Skobtsov DI; D'iachenko IA; Grishin EV
    Bioorg Khim; 2009; 35(6):789-98. PubMed ID: 20208578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRPV1 antagonists as a potential treatment for hyperalgesia.
    Roberts LA; Connor M
    Recent Pat CNS Drug Discov; 2006 Jan; 1(1):65-76. PubMed ID: 18221192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRPV1 channel modulation by hyaluronan reduces pain.
    de la Peña E; Gomis A; Ferrer-Montiel A; Belmonte C
    Channels (Austin); 2016; 10(2):81-2. PubMed ID: 26517313
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath.
    Tékus V; Bölcskei K; Kis-Varga A; Dézsi L; Szentirmay E; Visegrády A; Horváth C; Szolcsányi J; Petho G
    Eur J Pharmacol; 2010 Sep; 641(2-3):135-41. PubMed ID: 20534382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRPV1 signaling: mechanistic understanding and therapeutic potential.
    Xia R; Samad TA; Btesh J; Jiang LH; Kays I; Stjernborg L; Dekker N
    Curr Top Med Chem; 2011; 11(17):2180-91. PubMed ID: 21671876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diosmetin as a novel transient receptor potential vanilloid 1 antagonist with antinociceptive activity in mice.
    Adamante G; de Almeida AS; Rigo FK; da Silva Silveira E; Coelho YO; De Prá SD; Milioli AM; Camponogara C; Casoti R; Bellinaso F; Desideri AV; Santos MFC; Ferreira J; Oliveira SM; Trevisan G
    Life Sci; 2019 Jan; 216():215-226. PubMed ID: 30447303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 7-tert-Butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity.
    Nash MS; McIntyre P; Groarke A; Lilley E; Culshaw A; Hallett A; Panesar M; Fox A; Bevan S
    J Pharmacol Exp Ther; 2012 Aug; 342(2):389-98. PubMed ID: 22566669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Capsaicin receptor TRPV1].
    Tominaga M
    Brain Nerve; 2008 May; 60(5):493-501. PubMed ID: 18516971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
    García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
    J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analgesic potential of TRPV3 antagonists.
    Reilly RM; Kym PR
    Curr Top Med Chem; 2011; 11(17):2210-5. PubMed ID: 21671874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Involvement of TRPV1 in CNS signaling has opened up the possibility to develop TRPV1 drug therapies].
    Zygmunt P
    Lakartidningen; 2021 Dec; 118():. PubMed ID: 34894399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
    Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
    J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature.
    Reilly RM; McDonald HA; Puttfarcken PS; Joshi SK; Lewis L; Pai M; Franklin PH; Segreti JA; Neelands TR; Han P; Chen J; Mantyh PW; Ghilardi JR; Turner TM; Voight EA; Daanen JF; Schmidt RG; Gomtsyan A; Kort ME; Faltynek CR; Kym PR
    J Pharmacol Exp Ther; 2012 Aug; 342(2):416-28. PubMed ID: 22570364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.